CMR-Verified Myocardial Fibrosis is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients

doi:10.21203/rs.3.rs-166539/v1

Download PDF

Original Article

CMR-Verified Myocardial Fibrosis is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients

https://doi.org/10.21203/rs.3.rs-166539/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

The main cardiac features of primary aldosteronism (PA) are impaired left ventricular (LV) diastolic function, and some articles also reported more cardiac fibrosis in PA patients. However, the correlation between LV dysfunction and diffuse myocardial fibrosis in PA remains unknown. We enrolled 84 PA patients and 28 essential hypertension (EH) patients in West China Hospital. Cardiac magnetic resonance imaging (CMR) contrast enhancement was arranged for all subjects. Postcontrast T1 time and left ventricular myocardial strains and strain rates were measured. 76 PA patients and 27 essential hypertension (EH) patients were included in the final analysis. Blood pressure, LV mass indexes, and LV ejection fractions were comparable in both groups, while the global circumferential peak diastolic strain rate (PDSR) was lower (53 ± 20 vs. 68 ± 25, p<0.01) and the postcontrast T1 time was shorter (520 ± 38 vs. 538 ± 27, p=0.01) in PA patients than those in EH patients. Postcontrast T1 time (p=0.01) was independently related to global circumferential PDSR after adjusting for age and duration of hypertension in PA patients. Furthermore, plasma aldosterone concentration was negatively associated with myocardial T1 time (R=-0.261, p=0.023) in PA patients. The global circumferential PDSR derived by CMR is decreased, and the diffuse myocardial fibrosis is increased in PA patients compared to those in blood pressure matched EH patients. The severity of cardiac diastolic dysfunction independently relates to the degree of diffuse myocardial fibrosis in PA patients, and the diffuse myocardial fibrosis may be caused by high PAC level.

Trial registration number: ChiCTR2000031792.

Cardiac & Cardiovascular Systems

Primary aldosteronism

Essential hypertension

Left ventricular function

The global circumferential PDSR

Myocardial fibrosis

CMR

Primary aldosteronism (PA), characterized by increased aldosterone concentration, which cannot be suppressed by renin, is the most common endocrine cause of hypertension and contributes more than 10% to the etiology of hypertension [1] and 29.1% to the etiology of resistant hypertension [2]. In addition to high blood pressure, increased aldosterone, which has proinflammatory [3] and profibrotic effects [4] on myocardial tissues, is another risk factor for cardiovascular diseases. Previous clinical studies have shown that PA patients are prone to cardiovascular complications [5-7]. PA patients revealed a significantly higher prevalence of coronary artery disease (adjusted OR, 1.9), nonfatal myocardial infarction (adjusted OR, 2.6), heart failure (adjusted OR, 2.9), and atrial fibrillation (adjusted OR, 5.0) than essential hypertension (EH) patients [5]. Moreover, Reincke et al. [7] reported that cardiovascular mortality was the leading cause of death in PA (50%) and occurred less frequently in EH controls (34%).

It is well known that PA patients’ major cardiac damage is impaired left ventricular function [8,9], leading to poor prognosis in PA patients. The pathophysiological mechanism of left ventricular dysfunction in PA patients remains unclear. Studies have found that cardiac dysfunction results from fibrosis of the myocardium in many diseases, such as heart failure [10], hypertrophic cardiomyopathy [11], and diabetic patients [12]. As to if myocardial fibrosis increases in PA patients, the answer is still controversial [13-17]. Cardiac biopsy samples from four male PA patients exhibited 1.5-fold more fibrosis than those from EH patients (14% vs. 6%) [16]. A late gadolinium enhancement study using cardiac magnetic imaging (CMR) proved that patients with PA exhibit more frequent diffuse myocardial fibrosis than healthy volunteers [14] and EH patients [15]. Moreover, adrenalectomy was proven to reverse myocardial fibrosis in PA patients [17]. However, Gretaas et al. [13] reported that increased myocardial fibrosis was not found and may not represent a common clinical problem in PA.

CMR offers a non-invasive, highly accurate assessment of cardiac function and geometry, and contrast enhanced T1 mapping can provide evidence of diffuse myocardial fibrosis [12,18]. Post-contrast myocardial T1 time is inversely correlated with histologically defined interstitial fibrosis, so shorter contrast enhanced T1 time represents more interstitial fibrosis [19,20]. However, the correlation of left ventricle (LV) dysfunction and myocardial fibrosis in PA patients remains unknown. Thus, the aims of the prospective observational study were as follows: (1) to compare global contrast-enhanced T1 time between PA patients and age-, sex-, body mass index-, blood pressure-, and hypertension duration-controlled EH subjects; and (2) if the PA patients own shorter contrast-enhanced T1 time, we will try to explore the relationship between cardiac left ventricular function and myocardial fibrosis in PA patients.

Study population

From April 2018 to May 2019, 84 PA patients were recruited from the inpatient department of Endocrinology and Metabolism at West China Hospital. Twenty-eight age-, sex-, body mass index-, blood pressure-, and hypertension duration-matched EH subjects were included simultaneously. All the subjects were of Han ethnicity and between 22 and 78 years old. All the patients completed the initial screening test of the plasma aldosterone/renin ratio (ARR) for PA, plasm renin activity (PRA) < 0.2 ng/ml/h was set as 0.2 for the calculation of the ARR to avoid inflation due to a very low denominator. According to the guidelines, before the initial screening, all the subjects had been on stable antihypertensive treatment with an α1-adrenergic receptor antagonist alone or verapamil sustained-release agent or hydralazine, and with normal serum potassium levels. The PA patients were further diagnosed by confirmatory tests of saline infusion and/or captopril challenge according to current guideline [21]. The exclusion criteria included the following: ① subjects with a history of congestive heart failure, chronic steroid therapy or chronic kidney disease (estimated glomerular filtration rate < 60 ml/min); ② subjects with clinical indications of other secondary causes of hypertension except for PA, such as renal artery stenosis, pheochromocytoma, Cushing’s syndrome, and hyperthyroidism.

This study was revised and confirmed by the Ethics Committee of West China Hospital. Before the study, written informed consent was obtained from each individual. Our study was registered in the Chinese clinical trial registry (ChiCTR2000031792).

Demographic characteristics and laboratory determinations

Two trained staff members recorded the clinical characteristics of subjects with a standard questionnaire. Physical examination was performed on all the subjects, including body height, weight, waist circumference, and blood pressure. Body mass index (BMI) was computed as body weight in kilograms (kg) divided by height in meters squared (m²). The body surface areas were calculated as 0.0057×height (cm)+0.0121×weight (kg)+0.0882 for males and 0.0073×height (cm)+0.0127 ×weight (kg)-0.2106 for females. All patients underwent 24-hour ambulatory blood pressure monitoring three days before the CMR scan.

After overnight fasting (≥8 h), venous blood samples were collected to measure plasma aldosterone concentration (PAC), PRA, and other biochemical parameters. Radioimmunoassay was used to measure PAC and PRA (Beijing North Institute of Biotechnology Co., St Panjia Miao, Beijing). Serum potassium, serum sodium, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, pro-brain natriuretic peptide (pro-BNP), creatine kinase MB, troponin T, and myoglobin concentrations were measured for all patients using automated, standardized equipment by the Clinical Laboratory at West China Hospital.

Cardiovascular magnetic resonance protocol

CMR was performed with a 3.0 T MRI imager (Trio Tim; Siemens Medical Solution, Erlangen, Germany) using an eight-channel phased-array surface coil and prospective electrocardiographic triggering. Patients assumed a supine position, and ECG gating and respiratory gating were used throughout the scan. The cine images of the short-axis covering the LV and the long-axis (two-, three- and four-chamber views) were obtained with a segmented balanced steady-state-free-precession sequence. The scanning parameters were TR/TE 3.4/1.3 msec, flip angle 50°, a field of view 320-340 mm, matrix size 256×144, and section thickness, 8 mm with no gap.

Postcontrast T1 maps were acquired using modified look-locker inversion recovery sequence (total acquisition is 17 heartbeats, TR/TE 2.9/1.12 ms, 8 mm thickness, in-plane spatial resolution 2.4 mm × 1.8 mm, matrix size 192×144, flip angle 35°, bandwidth 930 Hz/pixel, TI of first experiment 100 ms, TI increment 80 ms, parallel imaging 2), which was recommended by the Society for Cardiovascular Magnetic Resonance [22]. Postcontrast T1 mapping was performed 15 minutes after the intravenous bolus injection administration of gadobenate dimeglumine (MultiHance; 0.5 mmol/ml; Bracco, Milan, Italy) at a dose of 0.15 mmol/kg body weight. Fig. 1 shows the contrast enhanced T1 maps of 2 PA patients and two EH patients.

CMR data analysis

All imaging data of PA patients and EH subjects were uploaded to Argus software (Siemens Healthcare, Erlangen, Germany). Two experienced radiologists blinded to clinical data defined the end-diastole, end-systole, and delineated LV endocardial and epicardial borders. LV end-diastolic volume, LV end-systolic volume, LV mass, and LV ejection fraction were then calculated, and volumes and mass were indexed to body surface area. The software also automatically calculated the global myocardial strain parameters, including radial, circumferential, and longitudinal peak strain (PS), peak systolic strain rate (PSSR), and peak diastolic strain rate (PDSR), and the intra- and inter-observer variability were calculated. To evaluate diffuse myocardial fibrosis, CVI42 software (Circle Cardiovascular Imaging, Calgary, Canada) was used to measure the value of postcontrast T1 time at the mid-layer myocardium of left ventricular basal, middle and apical segments.

Statistical analysis

Normally distributed data were expressed as the mean (±SD) for continuous variables, and categorical variables were expressed as percentages. Skewed variables were logarithmically transformed before analysis and expressed as medians (interquartile ranges). The quantitative variables were compared using a t-test, while the qualitative variables were compared using the χ2 test. Univariable analysis was performed to discover the correlation of the global circumferential PDSR and PSSR with postcontrast T1 time and other risk factors. The association of the global circumferential PDSR and PSSR with postcontrast T1 time in PA patients was analyzed with multivariate analysis. Variables included in the regression model were those parameters p ≤ 0.1 in univariable analysis. P ≤ 0.05 was considered statistically significant. Analyses were performed with SPSS 17.0 (Chicago, IL) for Windows.

Characteristics and metabolic parameters of PA and EH patients

All patients successfully underwent CMR except for nine patients (8 PA patients and 1 EH patient) who had severe arrhythmia, causing ECG synchronization failure during the study session. Therefore, 76 PA patients and 27 EH patients were included in the analysis. Table 1 shows the demographic characteristics and laboratory data of the subjects. Age, duration of hypertension, waist circumference, BMI, systolic blood pressure, and diastolic blood pressure did not significantly differ between the EH and PA groups. PA patients had higher PAC levels, ARR, high-density lipoprotein cholesterol, serum sodium, and pro-BNP than those in EH patients, and lower levels of PRA and serum potassium than those in EH patients.

CMR data in PA and EH patients

CMR results for LV mass, volumes, function, and contrast enhanced T1 mapping are summarized in Table 2. No significant differences were found in LV mass index, LV end-diastolic volume index, LV end-systolic volume index, and LV ejection fraction between PA patients and EH patients. As to T1 mapping, PA patients possessed significantly shorter post-T1 time (520 ± 38 vs. 538 ± 27, p=0.01).

Data on LV function are also presented in Table 2. The global circumferential PDSR (53 ± 20 vs. 68 ± 25, p<0.01) was decreased in PA patients than EH patients. Other LV function parameters, including the global radial, circumferential, and longitudinal PS, PSSR, and radial, longitudinal PDSR, did not show significant differences between the two groups.

Factors affecting global circumferential PDSR in PA patients

To further identify the parameters affecting global circumferential PDSR in PA patients, we used univariate analysis to demonstrate the relationship between global circumferential PDSR and potentially related factors. Global circumferential PDSR statistically related to age (R=0.39, p<0.01), duration of hypertension (R=-0.21, p=0.08) and contrast-enhanced myocardial T1 time (R=0.30, p=0.01).

Independent determinants of LV global PDSR in PA patients

Parameters that p ≤ 0.1 (Table 3) in univariable analysis were included in the multiple linear regression model. Specifically, age, hypertension duration, and myocardial T1 time were brought into the multiple linear regression of global circumferential PDSR. Table 4 showed the multiple linear regression results, which demonstrated that postcontrast T1 time was independently associated with the global circumferential PDSR (β = 0.257, p = 0.012, model R= 0.593) after adjusting for age and duration of hypertension.

Post-contrast myocardial T1 time negatively related to PAC in PA patients

As showed above, the global circumferential PDSR was lower in PA patients than EH patients, but PAC wasn't statistically related to global circumferential PDSR (p=0.58). However, Pearson’s analysis (Fig. 2) showed that PAC was negatively related to myocardial T1 time (R=-0.261, p=0.023).

Inter- and intra-observer variability of tissue tracking

Inter-observer variabilities of tissue tracking between two experienced radiologists were minimum, which were shown in Table 5. Correlation coefficient r were 0.749-0.957, p< 0.001 for all. Intra-observer variabilities for tissue tracking were r = 0.816-0.955, p< 0.001 for all. Myocardial tissue tracking was reproducible and reliable.

To the best of our knowledge, this is the first study to demonstrate a pathophysiological link between CMR-verified cardiac diastolic dysfunction and diffuse myocardial fibrosis assessed by postcontrast T1 time in PA patients. Although there was no significant difference was found in systolic cardiac functions between PA and EH patients, the global circumferential PDSR was lower, and the post-T1 time was shorter in PA patients than in blood pressure matched EH patients. In PA patients, postcontrast T1 time independently related to global circumferential PDSR after adjusting for confounding factors in the multivariate regression analysis. Additionally, the postcontrast T1 time is reversely related to PAC. Our study implies that diffuse myocardial fibrosis, which may be caused by elevated PAC level, affects left ventricular diastolic function, playing a crucial role in PA-associated cardiopathy.

In the present study, we also found that the global circumferential PDSR is a more sensitive indicator for identifying the left ventricular dysfunction in PA patients than ejection fraction, PS, and PSSR. Catena found that PA patients had lower left ventricular diastolic function than EH patients but no systolic function differences with echocardiographic measurements [8], which was similar to our finding. However, Catena [8] and Muiesan [23] also reported greater left ventricular mass in PA patients than in EH patients, but we did not see a significant difference in left ventricular mass in this study. This may be due to our PA patients' short disease course, which was not long enough to cause a marked increase in left ventricular mass.

Diastolic dysfunction plays a causative role in the process of cardiac failure [24]. In one study that included 6067 heart failure patients over 15 years, 47% of patients had a preserved ejection fraction, and the morbidity/mortality of preserved ejection fraction heart failure was comparable to that of reduced ejection fraction heart failure [25]. In our study, the median duration of hypertension was only four years, but the global circumferential PDSR was decreased in PA patients, indicating that even patients with a short PA course have already developed subclinical cardiomyopathy. Therefore, it is essential to assess cardiac function, especially diastolic function, but not only to ejection fraction in PA patients with a course of more than four years to identify subclinical cardiomyopathy.

If the myocardial fibrosis increases in PA patients, the answer is still controversial [13-16, 26]. Cardiac biopsy samples from four male PA patients exhibited 1.5-fold more fibrosis than those from EH patients (14% vs. 6%) [16]. A late gadolinium enhancement study using CMR imaging proved that patients with PA exhibit more frequent diffuse myocardial fibrosis than healthy volunteers [14,26] and EH patients [15,26]. However, Gretaas et al. [13] reported that increased myocardial fibrosis was not found and may not represent a common clinical problem in PA. In the present study, we found that diffuse myocardial fibrosis represented by postcontrast T1 time was increased in PA patients compared to blood pressure controlled EH patients. Abundant elementary experimental studies supported that aldosterone can promote myocardial fibrosis directly and indirectly. Aldosterone directly increases rat cardiac myofibroblast proliferation by activating Ki-RasA, the MAPK1/2 cascade [27], and insulin-like growth factor-I receptor [28]. Aldosterone also has an indirectly profibrogenic function by upregulating inflammation in cardiomyocytes [29] and inhibiting antifibrotic factors, including BNP and ANP [30]. Our study showed that the PAC was negatively related to myocardial T1 time, which indicates that the diffuse myocardial fibrosis may be caused by high PAC level.

We speculate that the different salt consumption of included patients may explain the different myocardial fibrosis results in PA patients in different research. From a rat model of hyperaldosteronism, the myocardial fibrosis only developed in rats with high salt intake [31], and Ang II type 1 receptor might have some implications in this model [32]. The habitual dietary sodium intake of the participants was not recorded in Gretaas’ study [13]. However, in Freel’s [15] and our study, patients were recruited in the local population with consuming a salt-rich diet, and myocardial fibrosis was increased. Besides, the serum sodium of PA patients was higher than EH patients in our study.

CMR-verified diffuse myocardial fibrosis was proved to associate with diastolic dysfunction in heart failure [10], hypertrophic cardiomyopathy [11], and diabetic patients [12], but it remains unknown in PA. Su [14] reported increased myocardial fibrosis and left ventricular mass in PA patients compared with healthy controls, but they did not perform a correlation analysis between these two parameters. Our study proved an independent relationship between the global circumferential PDSR and CMR-verified diffuse myocardial fibrosis, suggesting that hyperaldosteronism in PA may contribute to cardiac dysfunction by promoting myocardial fibrosis.

Our study had some limitations. Firstly, the myocardial biopsy is the gold standard for the diagnosis of cardiomyopathy. Considering its invasiveness and financial cost, we did not have histological evidence of myocardial fibrosis to validate the results of T1 mapping. Secondly, because this was a single-center study, there is a need for multicenter, large-scale trials to confirm our findings. Finally, the differences in the CMR strain analysis between PA and other secondary hypertension types are still unclear, so we cannot use CMR strain analysis for differential diagnosis of hypertension at present.

The global circumferential PDSR derived by CMR is decreased, and the diffuse myocardial fibrosis is increased in PA patients compared to those in blood pressure matched EH patients. The severity of cardiac diastolic dysfunction independently relates to the degree of diffuse myocardial fibrosis in PA patients, and the diffuse myocardial fibrosis may be caused by high PAC level.

Funding: This study was supported by West China Hospital, Sichuan University (Grant No. ZYGD18022 and 2018HXFH009), Department of Science and Technology of Sichuan Province (Grant No. 2019YJ0040, 2020YFS0123 and 2021YFS0198) and Health Department of Sichuan Province (Grant No. 20PJYY1108)

Conflicts of interest: The authors have no conflicts of interest to declare that are relevant to the content of this article.

Data availability: The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Code availability: Not applicable

Authors' contributions: FZ designed research, acquisition, and analysis of data, writing the manuscript. TW, WW, and SW collection of data. WC analysis of the data. HT, TC, and JS designed research. YR designed the study, revising the manuscript, and final approval the manuscript submitted.

Ethics approval: This study was revised and confirmed by the Ethics Committee of West China Hospital.

Consent to participate: Written informed consent was obtained from each participates.

Consent for publication: All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.

Acknowledgments

The authors thank the other investigators, staff, and participants of the ACWCH for their valuable contributions.

This study was supported by West China Hospital, Sichuan University (Grant No. ZYGD18022 and 2018HXFH009), Department of Science and Technology of Sichuan Province (Grant No. 2019YJ0040, 2020YFS0123 and 2021YFS0198) and Health Department of Sichuan Province (Grant No. 20PJYY1108)

Young WF, Calhoun DA, Lenders JWM, et al. (2017) Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. Endocrine Reviews 38:103-122.
Parasiliti-Caprino M, Lopez C, Prencipe N, et al. (2020) Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens 38:1841-1848.
Buonafine M, Martinez-Martinez E, Amador C, et al. (2018) Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J Mol Cell Cardiol 115:32-38.
Lijnen P, and Petrov V (2000) Induction of Cardiac Fibrosis by Aldosterone. Journal of Molecular and Cellular Cardiology 32:865-879.
Savard S, Amar L, Plouin P-F, et al. (2013) Cardiovascular Complications Associated With Primary Aldosteronism. Hypertension 62:331-336.
Milliez P, Girerd X, Plouin P-F, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45:1243-1248.
Reincke M, Fischer E, Gerum S, et al. (2012) Observational Study Mortality in Treated Primary Aldosteronism. Hypertension 60:618-624.
Catena C, Colussi G, Lapenna R, et al. (2007) Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism. Hypertension 50:911-918.
Cesari M, Letizia C, Angeli P, et al. (2016) Cardiac Remodeling in Patients With Primary and Secondary Aldosteronism. Circulation: Cardiovascular Imaging 9.
Su M-YM, Lin L-Y, Tseng Y-HE, et al. (2014) CMR-Verified Diffuse Myocardial Fibrosis Is Associated With Diastolic Dysfunction in HFpEF. JACC: Cardiovascular Imaging 7:991-997.
Ellims AH, Iles LM, Ling LH, et al. (2012) Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson 14:76.
Ng ACT, Auger D, Delgado V, et al. (2012) Association Between Diffuse Myocardial Fibrosis by Cardiac Magnetic Resonance Contrast-Enhanced T1Mapping and Subclinical Myocardial Dysfunction in Diabetic Patients. Circulation: Cardiovascular Imaging 5:51-59.
Grytaas MA, Sellevag K, Thordarson HB, et al. (2018) Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocr Connect 7:413-424.
Su M-YM, Wu V-C, Yu H-Y, et al. (2012) Contrast-enhanced MRI index of diffuse myocardial fibrosis is increased in primary aldosteronism. Journal of Magnetic Resonance Imaging 35:1349-1355.
Freel EM, Mark PB, Weir RAP, et al. (2012) Demonstration of Blood Pressure-Independent Noninfarct Myocardial Fibrosis in Primary Aldosteronism. Circulation: Cardiovascular Imaging 5:740-747.
Frustaci A, Letizia C, Verardo R, et al. (2019) Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization. Int J Cardiol 292:141-147.
Lin YH, Wu XM, Lee HH, et al. (2012) Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens 30:1606-1613.
Mascherbauer J, Marzluf BA, Tufaro C, et al. (2013) Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging 6:1056-1065.
Iles L, Pfluger H, Phrommintikul A, et al. (2008) Evaluation of Diffuse Myocardial Fibrosis in Heart Failure With Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping. Journal of the American College of Cardiology 52:1574-1580.
Sibley CT, Noureldin RA, Gai N, et al. (2012) T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology 265:724-732.
Funder JW, Carey RM, Mantero F, et al. (2016) The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:1889-1916.
Messroghli DR, Moon JC, Ferreira VM, et al. (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). Journal of Cardiovascular Magnetic Resonance 19.
Muiesan ML, Salvetti M, Paini A, et al. (2008) Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism. Hypertension 52:529-534.
Obokata M, Reddy YNV, and Borlaug BA (2020) Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging 13:245-257.
Owan TE, Hodge DO, Herges RM, et al. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251-259.
Redheuil A, Blanchard A, Pereira H, et al. (2020) Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans: A Proof-of-Concept Study by Cardiac Magnetic Resonance. JACC Cardiovasc Imaging 13:2149-2159.
Stockand JD, and Meszaros JG (2003) Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 284:H176-184.
Bunda S, Wang Y, Mitts TF, et al. (2009) Aldosterone Stimulates Elastogenesis in Cardiac Fibroblasts via Mineralocorticoid Receptor-independent Action Involving the Consecutive Activation of Gα13, c-Src, the Insulin-like Growth Factor-I Receptor, and Phosphatidylinositol 3-Kinase/Akt. Journal of Biological Chemistry 284:16633-16647.
Latouche C, Sainte-Marie Y, Steenman M, et al. (2010) Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart. Endocrinology 151:4467-4476.
Azibani F, Fazal L, Chatziantoniou C, et al. (2013) Aldosterone mediates cardiac fibrosis in the setting of hypertension. Curr Hypertens Rep 15:395-400.
Brilla CG, and Weber KT (1992) Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26:671-677.
Katayama IA, Pereira RC, Dopona EP, et al. (2014) High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation. J Nutr 144:1571-1578.

Table 1 Demographic characteristics and laboratory data of patients

Variable	EH (n=27)	PA (n=76)	P value
Age (yr)	46 ± 15	48 ± 11	0.62
Women (%)	15 (54)	54 (72)	0.16
Duration of hypertension (month)	72 (96)	36 (114)	0.42
Number of antihypertensive medications	2.2 ± 0.9	2.0 ± 1.1	0.35
Waist (cm)	89 ± 7	88 ± 10	0.80
BMI (kg/m2)	25 ± 3	25 ± 4	0.50
SBP (mmHg)	146 ± 11	145 ± 17	0.86
DBP (mmHg)	94 ± 12	93 ± 11	0.69
TG (mmol/L)	1.5 (0.9)	1.3 (0.9)	0.09
TC (mmol/L)	4.3 ± 1.0	4.5 ± 0.9	0.42
LDL-C (mmol/L)	2.5 ± 0.8	2.7 ± 0.7	0.29
HDL-C (mmol/L)	1.2 ± 0.4	1.4 ± 0.4	0.04
PAC (ng/dl)	23 ± 9	32 ± 12	<0.01
PRA (ng/ml/h)	3.0 (2.7)	0.2 (0.5)	<0.01
ARR (IU/L)	9 (6)	102 (104)	<0.01
K (mmol/L)	4.0 ± 0.4	3.5 ± 0.6	<0.01
Na (mmol/L)	141.7 ± 1.6	142.8 ± 2.2	0.02
Pro-BNP (pg/ml)	45 (38)	76 (93)	<0.01
CKMB (ng/ml)	1.0 (0.5)	1.1 (0.7)	0.32
TPN-T (ng/L)	6 (4)	7 (6)	0.64
Myo (ng/ml)	28 (15)	29 (11)	0.54

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; PAC: plasma aldosterone concentration; PRA: plasma renin activity; ARR: aldosterone-to-renin ratio; Pro-BNP: pro-brain natriuretic peptide; CKMB: creatine kinase MB; TPN-T: troponin T; Myo: myoglobin; PTH: parathyroid hormone.

Table 2 Comparison of CMR results between EH and PA patients

Variable	EH (n=27)	PA (n=76)	P value
LV massi (gm/m2)	58 ± 11	59 ± 16	0.87
LVEDVi (mL/ m2)	79 ± 14	81 ± 15	0.44
LVESVi (mL/ m2)	32 ± 9	34 ± 11	0.49
LVEF (%)	62 ± 11	59 ± 8	0.26
Myocardial T1 time (ms)	538 ± 27	520 ± 38	0.01
PS (%)
Radial	44 ± 7	43 ± 9	0.64
Circumferential	-15 ± 2	-15 ± 3	0.84
Longitudinal	-14 ± 2	-14 ± 3	0.80
PSSR (1/s)
Radial	219 ± 49	206 ± 51	0.26
Circumferential	-91 ± 20	-88 ± 22	0.47
Longitudinal	-76 ± 17	-72 ± 16	0.19
PDSR (1/s)
Radial	-164 ± 78	-132 ± 62	0.07
Circumferential	68 ± 25	53 ± 20	<0.01
Longitudinal	59 ± 17	60 ± 18	0.97

LVEDVi: Left ventricular end-diastolic volume index, LVESVi: left ventricular end-systolic volume index, LV massi: left ventricular mass indexed to body surface area, LVEF: left ventricular ejection fraction, PS: peak strain, PSSR: peak systolic strain rate, PDSR: peak diastolic strain rate.

Table 3 Univariable linear regression analysis for global circumferential PDSR in PA patients

Variable	Correlation Coefficient	P value
Age	0.39	<0.01
gender	-0.08	0.52
Ln Duration of hypertension	-0.21	0.08
BMI	0.11	0.37
SBP	0.05	0.68
DBP	-0.08	0.48
HDL-C	0.15	0.19
K	-0.17	0.15
Na	-0.05	0.68
PAC	0.07	0.58
Ln PRA	0.15	0.21
Ln ARR	-0.14	0.25
Ln Pro-BNP	-0.02	0.89
Myocardial T1 time	0.30	0.01

Abbreviations as in Table 1 and 2

Table 4 Independent determinants of LV global PDSR in PA patients

Variable	β	P value
Age (yr)	0.539	<0.001
Duration of hypertension	-0.321	0.004
Myocardial T1 time	0.257	0.012

Table 5 Inter-and intra-observer variability of tissue tracking

	Inter-observer r (n=20)	95%CI	Intra-observer r (n=20)	95%CI
PS (%)
Radial	0.909	0.757-0.977	0.955	0.7896-0.980
Circumferential	0.874	0.781-0.946	0.823	0.617-0.933
Longitudinal	0.802	0.561-0.965	0.932	0.832-0.978
PSSR (1/s)
Radial	0.941	0.873-0.983	0.940	0.843-0.982
Circumferential	0.939	0.784-0.995	0.887	0.756-0.954
Longitudinal	0.750	0.544-0.935	0.849	0.645-0.989
PDSR (1/s)
Radial	0.889	0.779-0.961	0.937	0.858-0.977
Circumferential	0.957	0.835-0.990	0.816	0.639-0.918
Longitudinal	0.749	0.501-0.945	0.878	0.595-0.996

Abbreviations as in Table 1 and 2

Download PDF

Version 1

posted

You are reading this latest preprint version

CMR-Verified Myocardial Fibrosis is Associated With Subclinical Diastolic Dysfunction in Primary Aldosteronism Patients

Status:

Version 1

Abstract

Figures

Introduction

Methods

Results

Discussion

Conclusions

Declarations

References

Tables

Status:

Version 1